Drug Profile
BVD 723
Alternative Names: BVD-723Latest Information Update: 31 Aug 2023
Price :
$50
*
At a glance
- Originator BioMed Valley Discoveries
- Class Antineoplastics; Small molecules
- Mechanism of Action Phosphatidylinositol 3 kinase gamma inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Cancer
Most Recent Events
- 31 Aug 2023 Discontinued - Preclinical for Cancer in USA (PO), prior to August 2023 (BioMed Valley Discoveries pipeline, August 2023)
- 28 Dec 2019 No recent reports of development identified for preclinical development in Cancer in USA (PO)
- 26 Oct 2017 Pharmacokinetics data from a preclinical study in Cancer presented at the 29th AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics (AACR-NCI-EORTC-2017)